ViroBlogy

Via Scoop.it – Virology News

NanoViricides (OTC:NNVC) said Monday that the U.S. health regulator gave a “good roadmap” toward an investigational new drug (IND) application for the company’s lead candidate FluCide, at a recent pre-IND meeting.
The previously announced meeting was held with the U.S. Food and Drug Administration on March 29, as scheduled.
NanoViricides said the meeting focused on FluCide, designated as NV-INF-1, the company’s anti influenza drug.

Via www.proactiveinvestors.com

This entry was posted on 3 April, 2012 at 09:24 and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.